𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

✍ Scribed by William Bara-Jimenez; Tzvetelina Dimitrova; Abdulah Sherzai; Antonella Favit; M.M. Mouradian; Thomas N. Chase

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
60 KB
Volume
19
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Dopamine reuptake blockers, by enhancing and stabilizing intrasynaptic transmitter levels, could help palliate motor dysfunction in Parkinson's disease. This randomized, double‐blind, placebo‐controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients. At the dose administered, no change in parkinsonian scores was found when NS 2330 was given alone or with levodopa. Moreover, NS 2330 coadministration did not appear to alter dyskinesia severity or the duration of the antiparkinsonian response to levodopa. The drug was well tolerated. Under the conditions of this study, the present results failed to support the usefulness of dopamine reuptake inhibition in the treatment of advanced Parkinson's disease. © 2004 Movement Disorder Society

📜 SIMILAR VOLUMES

Randomized trial of the triple monoamine
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
✍ Robert A. Hauser; Laurence Salin; Nolwenn Juhel; Victor L. Konyago 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

## Abstract The objective of this study was to evaluate the efficacy and safety of three daily dosages of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) compared to placebo as monotherapy in early Parkinson's disease (PD). In MPTP (1‐methyl 4‐phenyl‐tetrahydropyridine 1,2,3,6)‐lesion

Effects of serotonin 5-HT1A agonist in a
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease
✍ William Bara-Jimenez; Francesco Bibbiani; Michael J. Morris; Tzvetelina Dimitrov 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

## Abstract Intermittent stimulation of striatal dopaminergic receptors seems to contribute to motor dysfunction in advanced Parkinson's disease (PD). With severe dopaminergic denervation, exogenous levodopa is largely decarboxylated to dopamine in serotonergic terminals. If 5‐HT1A autoreceptors re

Effects of bilateral pallidal or subthal
Effects of bilateral pallidal or subthalamic stimulation on gait in advanced Parkinson's disease
✍ N. Allert; J. Volkmann; S. Dotse; H. Hefter; V. Sturm; H.-J. Freund 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 368 KB 👁 1 views

## Abstract Bilateral high‐frequency stimulation of the internal globus pallidus (GPi) and the subthalamic nucleus (STN) both alleviate akinesia, rigidity, and tremor in idiopathic Parkinson's disease. To test the specific effect of these procedures on gait, we used quantitative gait analysis in ad

A dose-ranging study of selegiline in pa
A dose-ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
✍ Nathalie Andreu; Christine Damase-Michel; Jean-Michel Senard; Olivier Rascol; Pr 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 337 KB 👁 1 views

## Abstract A dose‐ranging study of selegiline was performed in patients with Parkinson's disease to determine the minimal dosage of the drug able to inhibit ≥95% of platelet monoamine oxidase (MAO) activity. Different doses of selegiline (5 or 10 mg daily, 10 or 20 mg weekly) were studied in four

Effects of levodopa and COMT inhibitors
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients
✍ Paolo Lamberti; Stefano Zoccolella; Giovanni Iliceto; Elio Armenise; Angela Frad 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). T